2025肾癌研究峰会（The Kidney Cancer Research Summit）嘉宾演讲PPT合集（共50套打包）

1、Inducing Ferroptosis in ccRCC:Translating KCRP Discoveries to the ClinicMei Yee Koh,PhDAssociate Professor,University of UtahFounder and CEO,Kuda Therapeutics,IncDisclosure:I own stock and receive re。

2、Evaluating Global Disparities in Clinical Trial Availability for Renal Cell CarcinomaRuchi Agarwal1*,J.Goud2*,M.Zugman2,D.Castro2,X.Li2,K.Shah2,L.Lau2,A.Lee2,S.Jaime-Casas2,H.Ebrahimi2,G.Regalado-Por。

3、Real-World Evidence Shows No Survival Advantage with Contemporary First-Line Strategies in Papillary Renal Cell Carcinoma:A Call for Randomized TrialsMiguel Zugman,MDCity of HopePurpose To evaluate c。

4、Qinqin Jiang,PhDKaelin LabDana-Farber Cancer InstituteHIF Regulates Multiple Translated Endogenous Retroviruses in ccRCC:Implications for ImmunotherapyccRCC “Immunogenic Tumor”Occasionally regress sp。

5、Redesigning CAR T cells for solid tumors:A new path toward Cures of ccRCCWayne A Marasco,M.D.,Ph.D.Dana-Farber Cancer InstituteSLIDE DIMENSIONS SHOULD FOLLOW 16:9 RATIO G250 CAR-T in the Phase I clin。

6、Integrative clinical,genomic,transcriptomic,and immunopathologic characterizationof circulating KIM-1 in metastatic RCCMarc Machaalani1,Renee-Maria Saliby2,Caiwei Zhong1,Eddy Saad1,Clara Steiner1,Emr。

7、REGULATORY CONSIDERATIONS FOR RARE SUBTYPE TRIALS IN RCCCHANA WEINSTOCK,MDGU ONCOLOGY TEAM LEADEROFFICE OF ONCOLOGIC DISEASES,CDER,FDACURRENT TREATMENT LANDSCAPE IN RCCAlmost all approvals in metasta。

8、Exploring Health-Related Quality of Life Across Renal Cell Carcinoma:A Conceptual Domain Analysis.Koral Shah,MDCity of Hope Comprehensive Cancer CenterBACKGROUND=FKSI-23 Evaluating treatment outcomes。

9、Phase 2 trial of metastasis directed radiotherapy without systemic therapy(MRWS)for oligometastatic clear cell renal cell carcinoma(ccRCC)and investigation of circulating tumor DNA(ctDNA)as a persona。

10、Adjuvant Treatment OptionsNaomi B.Haas,MDAbramson Cancer CenterWhat have we learned from adjuvant therapy trials?Adjuvant pembrolizumab improved DFS and OS in pre-specified ccRCC at high and very hig。

11、Industry Support of Rare Subtype TrialsSumanta K.Pal,MD,FASCOProfessor&Vice Chair of Academic AffairsCity of Hope Comprehensive Cancer CenterImagine the landscape in metastatic clear cell renal c。

12、Personalized Vaccines in Kidney Cancer:A Journey from Concept to ClinicDavid A.Braun,MD,PhDAssistant Professor|Louis Goodman and Alfred Goodman Yale ScholarYale Cancer Center|Yale School of MedicineY。

13、Novel Imaging Approaches for Early Detection of Kidney CancerMark W.Ball,MD FACSNovel Imaging Approaches for Early Detection of Kidney CancerMark W.Ball,MD FACSObjectives Describe lifetime risk of RC。

14、Subsequent-Line Treatment for Advanced DiseaseRobert J.Motzer,MDJack and Dorothy Byrne Chair in Clinical OncologyAttending Physician and Member,MSKCCWhats new for KCRS 2025?TKIs HIF inhibitors Cellul。

15、Comprehensive Molecular Testing for Solid TumorsCaris Life SciencesBrian Liu,PhD.Whole Exome,Whole Transcriptome-Better StoryWES/WTS captures every detail,not just known biomarkersSLIDE DIMENSIONS SH。

16、A Genetic Perspective:Optimizing Screening for Individuals with Negative Germline TestingLindsey Byrne,MS,CGCLindsey.byrneosumc.eduObjectives Describe the role of Genetic Counselors in multidisciplin。

17、Memory-like Natural Killer(NK)Cell Immune Therapy in Patients with Renal Cell Carcinoma or Urothelial Carcinoma(NCT06318871)Wenxin(Vincent)Xu,Wanling Xie,Fuguo Liu,Grace Birch,Casey Welch,Maily Nguye。

18、ITMsITMs InvestigationalInvestigational CAIXCAIX-targetedtargetedRadiopharmaceuticalsRadiopharmaceuticals forfor Diagnosis and Diagnosis and Treatment Treatment ofof Patients with Patients with ccRCC。

19、CD3 T Cell Engagers The Next Wave of IOCharles G.Drake,MD,PhD,MS,FAAP1Disclosure InformationCharles G.DrakeI am a paid employee of Johnson and Johnson Innovative MedicineI have an adjunct appointment。

20、Essential Biomarkers in RCCWenxin(Vincent)Xu,MDAssistant Professor of MedicineDana-Farber Cancer InstituteDisclosuresEXCLUSION ZONEResearch funding:DOD CDMRP KCRP AcademyASCO/Conquer Cancer Foundatio。

21、Short TeRm Intensified Pembrolizumab(KEytruda)and Tivozanib for High-risk renal cell carcinoma-STRIKE!(AO32201)Bradley A McGregor,MDMarra Lochiatto Investigatorship in Kidney CancerDana Farber Cancer。

22、Kidney Cancer Research ConsortiumERIC JONASCH,MD ON BEHALF OF THE KCRC TEAM AND INVESTIGATORSDr.David McDermottDr.Hans HammersDr.Naomi HaasDr.Eric JonaschDr.Brian RiniDr.Ulka VaishampayanDr.Daniel Ge。

23、Investigating the Mechanisms of Neoadjuvant Olaparib and Cediranib in Renal CancerResults of Arms 1 to 3 of the WIndow of opportunity in REnal cancer(WIRE)Clinical TrialDr James Jones PhD MRCPWIRE Tr。

24、Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma:results from an expansion cohort of ARC-20(NCT05536141)Toni K Choueiri,MD,FASCO1;Moshe Orn。

25、Clinical Trial Design and ExecutionLessons Learned from Other CancersVivek Subbiah,MDNashville,TN,USAMy personal perspectives on Tumor-agnostic drug developmentEvery target is a pan-target Tumors don。

26、FIRST LINE SYSTEMIC THERAPY STRATEGIESDavid McDermott,MDBeth Israel Deaconess Medical CenterHarvard Medical SchoolDisclosure InformationEXCLUSION ZONEContent Consultant for:BMS,Pfizer,Merck,Iovance,E。

27、Strategies for Patients with Rare SubtypesMehmet Asim Bilen,MD mbilenemory.eduWinship Cancer Institute of Emory UniversityConflict of Interest Advisory board:Exelixis,Bayer,BMS,Eisai,Pfizer,AstraZene。

28、Statistical Approaches for Designing and Conducting Rare Subtype TrialsWanling XieDana Farber Cancer InstituteJuly 17,2025DisclosureConsulting to PCCTC Convergent TherapeuticsMarchetti et al,Int J Mo。

29、Characterizing Carbonic Anhydrase 9 and HIF-2 RNA Expression in Clear Cell Renal Cell CarcinomaYu-Wei Chen1,Shayan S.Nazari2,Andrew Elliott2,Ninad Kulkarni2,Norm Smith2,Rasha Nawfal3,Pedro Barata4,Br。

30、Risk Stratified Screening for Kidney CancerGrant D StewartProfessor of Surgical Oncology,University of CambridgeHonorary Consultant Urologist,Addenbrookes Hospital,Cambridge,UKDisclosuresNICENational。

31、The State of Screening Individuals with a Hereditary Risk of Kidney CancerMarie Carlo,MDGenitourinary Oncology Medical GeneticsMemorial Sloan Kettering Cancer Center Learning Objectives Distinguish p。

32、The actionable microbial gut checkpoint MAdCAM-1 in patients with advanced renal cell carcinomaCarolina Alves Costa Silva,MD,PhDOncoclnicas Group/Oswaldo Cruz Foundation/Federal University of Bahia,S。

33、The Future of Cancer VaccinesClinical Director,Melanoma CenterDana Farber Cancer InstituteProfessor of MedicineHarvard Medical SchoolDisclosuresAdvisory Role:Alexion,Array,Bristol-Myers Squibb,Cellde。

34、Patient Advocacy,Registry,and Trial Recruitment:What Has Worked in Rare CancersJoshua Mann,MPHDirector of HealthVHL Alliancejosh.mannvhl.orgThe VHL Alliance Founded in 1993 by patients and families a。

35、Lower Checkpoint Gene Expression is Associated with Primary Resistance to Nivolumab-Ipilimumab Combination in Advanced Renal Cell CarcinomaRana R.McKay1,Adam J.Dugan2,Unnati Jariwala2,Karyn Ronski2,J。

36、Novel Therapies Outside Immunotherapy in RCCThai H.Ho,MD,PhDAssociate ProfessorBlatt-Ness Endowed Oncology ChairHollings Cancer Center Medical University of South CarolinaDisclosuresAdvisory board/co。

37、Influence of sex on immunosurveillance and metastatic tropism in novel mouse models of clear cell renal cell carcinomaDoris Zheng1,2,Hui Jiang1,2,Nicole Rittenhouse1,2,Amrita Nargund Mangalvedhekar1,。

38、Updates in Papillary RCCBradley A McGregor,MDMarra Lochiatto Investigatorship in Kidney Cancer ResearchDirector of Clinical ResearchLank Center for GU Oncology,Dana Farber Cancer InstituteWhat is Pap。

39、Overcoming Innate and Adaptive Resistance in RCCCombination of the Next-Generation Farnesyl Transferase Inhibitor,KO-2806,with a VEGF Receptor Tyrosine Kinase InhibitorJabed Seraj,MD Kura Oncology,In。

40、LASER a Phase 2 trial of 177Lu-PSMA-617 as Systemic Therapy for Renal Cell CarcinomaPraful Ravi,Wanling Xie,Stephanie Berg,Michael Serzan,Bicky Thapa,Srinivas Viswanathan,Wenxin Xu,Bradley McGregor,T。

41、Alt:Metabolizing and adapting in a complex cancer environmentW.Kimryn Rathmell Kimryn RathmellKeynote:Leading the Way in Fostering Early Careers with a Focus on Kidney CancerConflict of Interest Disc。

42、CD163 Tumor-Associated Macrophages and Clinical Outcomes to First-Line Nivolumab Therapy in Patients with Metastatic Clear Cel Renal Cell Carcinoma:Insights from the HCRN GU16-260 Trial Berkay Simsek。

43、Phase II trial of ivonescimab in previously treated patients with advanced clear cell renal cell carcinoma(IVORY)Nazli Dizman,MDUniversity of Texas MD Anderson Cancer CenterNCT06940518Introduction/Me。

44、Novel Targets for CellularTherapies in RCCRosa Nadal Rios.MD.PhD.Associate ProfessorUniversity of Washington School of MedicineFred Hutch Cancer CenterDifferent Tumor Antigen TypesTumor AntigensTumor。

45、Biology and Therapeutic Vulnerabilities:Needs and OpportunitiesYing-Bei Chen,MD,PhDAttending PathologistDepartment of Pathology and Laboratory MedicineMemorial Sloan Kettering Cancer CenterVariant 4:。

46、At the PEAK of ccRCC,HIF-2 Drug Development eVOLVEs Casdatifan Initiates Phase 3 TrialsJonathan Yingling,Chief Scientific Officer,Arcus BiosciencesHIF-2 Is a Key Driver in the Development and Progres。

47、From Bench to Bedside:Advancing KIM-1 as a Tool for Clinical Decision-MakingWenxin(Vincent)Xu,MDAssistant Professor of MedicineDana-Farber Cancer InstituteDisclosuresResearch funding:DOD CDMRP KCRP A。

48、A Phase 1 study of XmAb819(ENPP3 x CD3)in subjects with relapsed or refractory clear cell renal cell carcinoma(ccRCC)Ritesh KotechaMemorial Sloan Kettering Cancer CenterProprietary;do not reproduceIn。